|
Janssen Resubmits Xarelto sNDA, Answers Complete Response Letter
Following setbacks in recent months for Janssen’s blood-clot drug Xarelto, the company has responded to an FDA complete response letter (CRL) on one sNDA for the drug and has re-submitted a separate sNDA.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives